PBParaskevi Boura

Paraskevi Boura

*This is an algorithmically generated author record based on publicly available information.

Paraskevi Boura has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bevacizumab-Induced Hypertension

    by Kostas N. Syrigos, Eleni Karapanagiotou, Paraskevi Boura, Christian Manegold, Kevin Harrington

    Bevacizumab, a recombinant humanized monoclonal antibody targeting the vascular endothelial growth factor (VEGF), has been approved in the US as first- and second-line treatment of colorectal cancer...


    • 1 October 2009
      • Vol. 29  (10) , 4297-301

    Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.

    by Eleni M Karapanagiotou, Paraskevi G Boura, George Papamichalis, Marios Konstantinou, Evangellos Sepsas, George Chamalakis, Panagiotis Simsiris, Ioannis Gkiozos, Kostas N Syrigos

    The aim of this study was to determine the progression-free survival (PFS) and toxicity associated with adjuvant administration of carboplatin and pemetrexed for completely resected patients with stage IB, II and IIIA non-small cell lung cancer (NSCLC). Forty-five eligible NSCLC patients received surgical resection for pathological stage IB, II or IIIA followed by postoperative adjuvant chemotherapy with carboplatin AUC5 and pemetrexed administered on days 1 and 14 on a 28-day cycle. Recombinant human granulocyte colony-stimulating factor (rhG-CF) was given prophylactically. The mean time to disease progression of patients was 26 months. Toxicities were generally mild to moderate and entirely manageable. The administration of carboplatin and pemetrexed is a safe, well-tolerated and convenient regimen in the adjuvant setting of completely resected NSCLC, with efficacy similar to that reported in other regimens but less toxicity.


    • 1 April 2009
      • Vol. 8  (2) , 106-9

    Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.

    by Ekaterini I Syrigou, Eleni M Karapanagiotou, Christina V Alamara, Paraskevi G Boura, Muhammad W Saif, Kostas N Syrigos

    We recorded the epidemiologic and clinical features of hypersensitivity reactions (HSRs) to oxaliplatin in colorectal cancer (CRC) patients in order to provide information on the management of these patients. We also developed a desensitization protocol and evaluated its clinical application. For these reasons, we analyzed retrospectively the records of 215 CRC patients treated with oxaliplatin-containing regimens either as an adjuvant, first-line, second-line, or more. Data from 52 patients with HSRs were analyzed according to the Common Toxicity Criteria for Adverse Events (CTCAE), v3.0. Three patients were chosen for the desensitization protocol. After determining the starting point for desensitization, we applied the standard protocol for parenteral desensitization to b-lactam antibiotics. Oxaliplatin treatment was then carried out with serial 10-fold dilutions in sufficient volume to administer the total dose. A total of 52 patients (24.2%) were recorded as having an allergic reaction to oxaliplatin. Hypersensitivity reactions were recorded after a mean of 6.5 (SD +/- 4.5) cycles. Only 4 patients (4 of 215; 1.8%) developed CTCAE grade 3/4 HSRs. Hypersensitivity reactions were seen more likely in patients receiving second-line or more of chemotherapy compared with chemotherapy-naive patients. No other correlations were seen (the presence of atopic disease, positive skin prick test). The 3 patients, having completed the parenteral desensitization protocol, completed their treatment uneventfully as well. Hypersensitivity reactions from oxaliplatin respond quickly to the discontinuation of the drug and appropriate support. Premedication and an increased infusion time could allow for readministration. The desensitization protocol we developed can provide a reliable alternative to permanent discontinuation of oxaliplatin.